Professor Rodgers Wins NSW Cardiovascular Research Excellence Award | 2025 Ministerial Award
- A leading Australian cardiovascular researcher, Professor Anthony Rodgers, has been awarded the 2025 Ministerial Award for Cardiovascular Research Excellence.
- Professor Rodgers, who has authored over 600 peer-reviewed publications in prestigious medical journals including The Lancet, JAMA, NEJM, and BMJ, has also secured more than $100 million in...
- His most notable achievement centers around the development of a low-dose triple combination pill for hypertension.
A leading Australian cardiovascular researcher, Professor Anthony Rodgers, has been awarded the 2025 Ministerial Award for Cardiovascular Research Excellence. The award, presented on , at the NSW Cardiovascular Research Network (CVRN) Showcase and Awards Ceremony at the Art Gallery of NSW in Sydney, recognizes a lifetime of contributions to breakthroughs in cardiovascular disease.
Professor Rodgers, who has authored over 600 peer-reviewed publications in prestigious medical journals including The Lancet, JAMA, NEJM, and BMJ, has also secured more than $100 million in competitive research grants throughout his 30-year career. However, the award specifically acknowledges his success in translating complex research into practical, real-world solutions for patients.
His most notable achievement centers around the development of a low-dose triple combination pill for hypertension. Professor Rodgers spearheaded the project from its initial conceptualization through to its global impact. The therapy received FDA approval in 2025 and was subsequently added to the World Health Organization (WHO) Essential Medicines List – a critical step in ensuring access to vital medications worldwide.
Beyond its approval as a treatment for high blood pressure, the combination pill has demonstrated promising results in stroke prevention. Data from the landmark TRIDENT trial indicate that the therapy can reduce the risk of a secondary stroke event by 40%. This finding underscores the potential for a single pill to address multiple cardiovascular risks simultaneously.
To further facilitate access to this innovative therapy, The George Institute’s venture-backed spin-off, George Medicines, has successfully raised $70 million in funding. This investment aims to make the new treatment available to patients globally, establishing New South Wales as a prominent hub for hypertension combination therapy research, and development.
Professor Rodgers’ contributions extend beyond direct patient care and research. He has also mentored 18 PhD students, fostering the next generation of cardiovascular researchers. He currently leads MAGNET, Australia’s first national adult mental-health trials network, demonstrating a commitment to addressing the intersection of physical and mental health.
Professor Alta Schutte, who nominated Professor Rodgers for the award, described him as “an outstanding candidate” whose achievements exemplify exceptional scientific innovation and long-term capacity building for cardiovascular research within New South Wales.
Hypertension, or high blood pressure, remains a leading cause of cardiovascular disease worldwide. Despite its prevalence, control rates remain suboptimal, highlighting the need for innovative and accessible treatment options. The development of low-dose combination pills represents a significant step forward in addressing this public health challenge. By simplifying treatment regimens and improving adherence, these therapies offer a scalable solution with the potential to benefit millions globally.
The award comes as the NSW Cardiovascular Research Network (CVRN) celebrates two decades of excellence in cardiovascular research. The CVRN’s 20-year anniversary was marked at the same ceremony where Professor Rodgers received his award, highlighting the network’s ongoing commitment to advancing heart health in the region.
Professor Rodgers’ work also builds on a growing body of evidence supporting the use of polypills – single tablets containing multiple medications – as a strategy to improve cardiovascular health outcomes. His success in navigating the regulatory pathways for FDA approval and WHO inclusion paves the way for wider adoption of this approach to managing chronic conditions.
The development and implementation of this new therapy represent a significant achievement in translational research – the process of converting scientific discoveries into practical applications that benefit patients. Professor Rodgers’ dedication to this process, coupled with his prolific research output and mentorship of future scientists, solidifies his position as a leader in the field of cardiovascular medicine.